Track topics on Twitter Track topics that are important to you
Murrieta Genomics will showcase SeqOnce’s technology and products in its incubator facility, providing information and demonstrations to potential customers. Murrieta Genomics will also assist SeqOnce with product development by testing and using its products in the Murrieta laboratory.
MURRIETA, Calif. (PRWEB) February 20, 2019
Murrieta Genomics, the genomic sequencing business incubator and SeqOnce, an emerging leader in the rapidly growing NGS (Next Generation Sequencing) field, have announced a partnership to bring fast and simple sample solutions for the Murrieta Genomics laboratory and incubator.
"As an innovation center and idea incubator, we are always looking for new applications in the genomic sequencing space and the RhinoSeq™ kits from SeqOnce have huge promise,” stated Brandon Young, a co-founder of Murrieta Genomics and the company’s Director of Laboratory Operations. “RhinoSeq is a remarkably fast and easy-to-use product for library preparation that will disrupt the growing NGS market. We see Rhinoseq reducing library construction time from a multi-hour process to less than 45 minutes, producing consistently excellent results across a wide range of sample types and inputs. We are excited to team with SeqOnce to develop, showcase and demonstrate their libraries to our growing base of customers and incubator companies."
“The proprietary chemistry in RhinoSeq reduces the preparation time of NGS samples by several fold over other library preparation methods,” explained SeqOnce CEO Chris Angermayer. “The technology can be applied to DNA from any sample source and can be adapted to most sequencing applications and automation platforms. Having access to the Murrieta Genomics lab and its partners provides us with new development and distribution opportunities.”
Under the agreement, Murrieta Genomics will showcase SeqOnce’s technology and products in the incubator facility, providing information and demonstrations to potential customers. Murrieta Genomics will also assist SeqOnce with product development by testing and using its products in the Murrieta laboratory.
The fact that Murrieta Genomics will be sequencing genetic material from diverse sources across multiple applications was a plus for SeqOnce. “We really like that Murrieta Genomics accesses and advances a broad range of genomic sequencing technologies, as this approach fits perfectly with our concept of developing robust sample preparation libraries,” Angermayer concluded.
About Murrieta Genomics
Murrieta Genomics provides access to next generation sequencing technology for researchers in the health, veterinary, agriculture, forensics and direct to consumer industries. The company is a true business incubator, offering mentorship and guidance from both the scientific and business perspective to aspiring genomic-related entrepreneurs. The founders of Murrieta Genomics have extensive background in business, finance, science and technology. They are supplemented with a prestigious advisory board from both business and science. In addition to low-cost incubation, the company provides hands-on consulting and will provide seed funding to qualified incubator graduates and connections to next-stage funders. For more information visit http://www.murrietagenomics.com.
About SeqOnce Biosciences, Inc.
SeqOnce Biosciences is a life science company developing innovative products for Next Generation Sequencing (NGS) that addresses critical needs in the research and clinical markets. Additional technologies and novel products for NGS library construction applications are pipelined and undergoing validation. Learn more at http://www.seqonce.com
For the original version on PRWeb visit: https://www.prweb.com/releases/murrieta_genomics_and_seqonce_biosciences_team_to_simplify_and_commercialize_next_generation_sequencing_sample_preparation/prweb16115417.htmNEXT ARTICLE
DNA sequencing is the process of determining the precise order of nucleotides within a DNA molecule. During DNA sequencing, the bases of a small fragment of DNA are sequentially identified from signals emitted as each fragment is re-synthesized from a ...
Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...